Abstract: Provided are liposomes including a lipid membrane enclosing an intraliposomal compartment. The liposomes may encapsulate an iron complex, including an iron moiety and a macromolecule, in the intraliposomal compartment. The liposomes may additionally have a targeting moiety associated with the liposomal membranes. The targeting moiety may be exposed at the liposome's outer surface. The liposomes exhibit an immunomodulatory effect or anti-cancer effect depending on the molar ratio between the lipids forming the lipid membrane and the iron complex. As such, the liposomes can be used to treat types of inflammation, particularly inflammations that are not associated or caused by infection or be used to treat cancer. Further provided are compositions including the disclosed liposomes, methods of using and kits including the liposomes.

Abstract: In accordance with the present disclosure there are provided iron oxide nanoparticles for use in the treatment of non-infectious inflammatory disorders. Also provided by the present disclosure is a method of treatment of non-infectious inflammatory disorders making use of such particles, pharmaceutical compositions and kits comprising such particles.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: In accordance with the present disclosure there are provided iron oxide nanoparticles for use in the treatment of non-infectious inflammatory disorders.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Abstract: Subject of the present invention is the use of a Factor XIII-preparation preferably in injectable form for the treatment of diseases which are associated with disturbed blood perfusion of the tissue following transient or permanent ischemia.

Abstract: The invention is directed to tissue-engineered biografts, methods for preparing the biografts of the invention, and methods for repairing a damaged myocardium in a mammal. The methods of the invention can include providing a three-dimensional porous polysaccharide matrix; introducing mammalian cells into said matrix; growing said cells in said matrix in vitro, until a tissue-engineered biograft is formed; and transplanting the tissue-engineered biograft onto myocardial tissue or myocardial scar tissue of said mammal. The tissue-engineered biograft of the invention can form a contracting tissue. The methods of the invention can optionally include removing scar tissue or dead tissue from the site of implantation prior to transplanting the biograft.

Abstract: A method for repairing a damaged myocardium in a mammal, comprising: a) providing a three-dimensional porous polysaccharide matrix; b) introducing mammalian cells into said matrix; c) growing said cells in said matrix in vitro, until a tissue-engineered biograft is formed, comprising a contracting tissue; and d) transplanting the tissue-engineered biograft onto the myocardial tissue or myocardial scar tissue of said mammal, optionally previously removing scar or dead tissue from the site of implantation.